We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 24, 2021

Impact of Rituximab Biosimilars on Overall Survival in Diffuse Large B-Cell Lymphoma

Blood advances

 

Additional Info

Blood advances
Impact of Rituximab Biosimilars on Overall Survival in Diffuse Large B-Cell Lymphoma: A Dutch Population-Based Study
Blood Adv 2021 Aug 10;5(15)2958-2964, M Brink, XU Kahle, JSP Vermaat, JM Zijlstra, M Chamuleau, MJ Kersten, M Durmaz, WJ Plattel, PJ Lugtenburg, W Stevens, R Mous, EGE de Vries, MWM van der Poel, PVN Panday, G Huls, T van Meerten, M Nijland

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading